Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016', provides in depth analysis on Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted pipeline therapeutics. 

The report provides comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) 
- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Overview 7
Therapeutics Development 8
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Products under Development by Stage of Development 8
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Products under Development by Therapy Area 9
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Products under Development by Indication 10
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Products under Development by Companies 13
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development 21
Alteogen Inc. 21
Chengdu Kanghong Pharmaceuticals Group Co Ltd 22
Clearside BioMedical, Inc. 23
Formycon AG 24
Regeneron Pharmaceuticals Inc 25
ThromboGenics NV 26
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles 27
(aflibercept + nesvacumab) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(aflibercept + rinucumab) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(aflibercept + triamcinolone acetonide) - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
aflibercept - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
aflibercept biosimilar - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
aflibercept biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
conbercept - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
SL-186 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SL-188 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
TG-931 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
THR-317 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ziv-aflibercept - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Projects 59
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products 60
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Featured News & Press Releases 61
Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 61
Sep 30, 2016: Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration 61
Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 62
Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 63
Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 64
May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 65
May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 65
Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 66
Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 67
Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 68
Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 68
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 69
Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 70
Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 70
Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Alteogen Inc., H2 2016 21
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2016 22
Pipeline by Clearside BioMedical, Inc., H2 2016 23
Pipeline by Formycon AG, H2 2016 24
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25
Pipeline by ThromboGenics NV, H2 2016 26
Dormant Projects, H2 2016 59
Discontinued Products, H2 2016 60